GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in Apolipoprotein E-null mice

Molecular Therapy

Volumn 24, Issue 11, 2016, Pages 1926-1938

  Mei, Wen ^a   Xiang, Guangda ^a   Li, Yixiang ^b   Li, Huan ^a   Xiang, Lingwei ^c   Lu, Junyan ^a   Xiang, Lin ^a   Dong, Jing ^a   Liu, Min ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; APOLIPOPROTEIN E; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSTATIN; PALMITIC ACID; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; GDF11 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; RAW 264.7 CELL LINE; T LYMPHOCYTE; ADMINISTRATION AND DOSAGE; ANIMAL; CELL CULTURE; CYTOLOGY; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; PHARMACOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; GROWTH DIFFERENTIATION FACTORS; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; PALMITIC ACID; RAW 264.7 CELLS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85002828840     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.160     Document Type: Article

References (46)

1. Gamer LW, Wolfman NM, Celeste AJ, Hattersley G, Hewick, R, and Rosen V. (1999) A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol 208: 222-232.
2. Oh SP, Yeo CY, Lee Y, Schrewe H, Whitman, M, and Li E. (2002). Activin type IIA, and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev 16: 2749-2754.
3. 3, and ersson O, Reissmann, E, and Ibanez CF. (2006). Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO Rep 7: 831-837.
4. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, et al. (2013). Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153: 828-839.
5. Sinha M, Jang YC, Oh J, Khong D Wu EY, Manohar R, et al. (2014). Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344: 649-652.
6. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, et al. (2014). Vascular, and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344: 630-634.
7. Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, et al. (2015). GDF11 increases with age, and inhibits skeletal muscle regeneration. Cell Metab 22: 164-174.
8. Smith SC, Zhang X, Zhang X, Gross P, Starosta T, Mohsin S, et al. (2015). GDF11 does not rescue aging-related pathological hypertrophy. Circ Res 117: 926-932.
9. Poggioli T, Vujic A, Yang P, Macias-Trevino C, Uygur A, Loffredo FS, et al. (2016). Circulating growth differentiation factor 11/8 levels decline with age. Circ Res 118: 29-37.
10. Fadini GP, Menegazzo L, Bonora BM, Mazzucato M, Persano S, Vigili de Kreutzenberg S, et al. (2015). Effects of age, diabetes, and vascular disease on growth differentiation factor 11: first-in-human study. Diabetes Care 38: e118-e119.
11. Heidecker B, Olson K, Beatty A. (2015). Low levels of growth differentiation factor 11, and high levels of its inhibitor follistatin-like 3 are associated with adverse cardiovascular outcomes in humans. J Am Coll Cardiol 65: A999.
12. Olson KA, Beatty AL, Heidecker B, Regan MC, Brody EN, Foreman T, et al. (2015). Association of growth differentiation factor 11/8, putative anti-Ageing factor, with cardiovascular outcomes, and overall mortality in humans: analysis of the heart, and soul, and HUNT3 cohorts. Eur Heart J 36: 3426-3434.
13. Zhang L, Connelly JJ, Peppel K, Brian L, Shah SH, Nelson S, et al. (2010). Agingrelated atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models, and human association studies. Hum Mol Genet 19: 2754-2766.
14. Mattace-Raso F, van Popele NM, Schalekamp, MA, and van der Cammen TJ. (2002). Intima-media thickness of the common carotid arteries is related to coronary atherosclerosis, and left ventricular hypertrophy in older adults. Angiology 53: 569-574.
15. Bos D, van der Rijk MJ, Geeraedts TE, Hofman A, Krestin GP, Witteman JC, et al. (2012). Intracranial carotid artery atherosclerosis: prevalence, and risk factors in the general population. Stroke 43: 1878-1884.
16. Jalkanen J, Leppanen P, Pajusola K, Narvanen O, Mahonen A, Vahakangas E, et al. (2003). Adeno-Associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther 8: 903-910.
17. Finkenzeller G, Stark, GB, and Strassburg S. (2015). Growth differentiation factor 11 supports migration, and sprouting of endothelial progenitor cells. J Surg Res 198: 50-56.
18. Birck MM, Saraste A, Hyttel P, Odermarsky M, Liuba P, Saukko P, et al. (2013). Endothelial cell death, and intimal foam cell accumulation in the coronary artery of infected hypercholesterolemic minipigs. J Cardiovasc Transl Res 6: 579-587.
19. Bonetti PO, Lerman, LO, and Lerman A. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175.
20. Galis, ZS, and Khatri JJ. (2002). Matrix metalloproteinases in vascular remodeling, and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262.
21. Libby P. (2002). Inflammation in atherosclerosis. Nature 420: 868-874.
22. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, et al. (2003). Elevation of free fatty acids induces inflammation, and impairs vascular reactivity in healthy subjects. Diabetes 52: 2882-2887.
23. Hansson GK, Libby P, Schonbeck, U, and Yan ZQ. (2002). Innate, and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91: 281-291.
24. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, et al. (2012) A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function, and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59: 265-276.
25. Moncada S, Palmer, RM, and Higgs EA. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
26. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski, T, and Luscher TF. (1998). Reduced endothelial nitric oxide synthase expression, and production in human atherosclerosis. Circulation 97: 2494-2498.
27. Michell BJ, Chen Zp, Tiganis T, Stapleton D, Katsis F, Power DA, et al. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C, and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628.
28. Zhang YH, Cheng F Du XT, Gao JL, Xiao XL, Li N, et al. (2016). GDF11/BMP11 activates both smad1/5/8, and smad2/3 signals but shows no significant effect on proliferation, and migration of human umbilical vein endothelial cells. Oncotarget 7: 12063-12074.
29. Tuttolomondo A. (2012). Editorial: treatment of atherosclerosis as an inflammatory disease. Curr Pharm Des 18: 4265.
30. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. (2002). Insulin causes endothelial dysfunction in humans: sites, and mechanisms. Circulation 105: 576-582.
31. Lteif AA, Han, K, and Mather KJ. (2005). Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites, and blacks. Circulation 112: 32-38.
32. Shiomi M, Ito T, Hirouchi, Y, and Enomoto M. (2001). Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 157: 75-84.
33. Glass CK, Witztum JL. (2001). Atherosclerosis: the road ahead. Cell 104: 503-516.
34. Gough PJ, Gomez IG, Wille, PT, and Raines EW. (2006). Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 116: 59-69.
35. Guo, X, and Wang XF. (2009). Signaling cross-Talk between TGF-beta/BMP, and other pathways. Cell Res 19: 71-88.
36. Senokuchi T, Matsumura T, Matsuo T, Yano M, Nishikawa T, Araki E. (2003). 4P-0977 Extracellular signal-regulated kinase, and p38 mitogen-Activated protein kinases are involved in oxidized low density lipoprotein-induced macrophage proliferation. Atherosclerosis Supp 4: 289.
37. Chang, L, and Karin M. (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
38. Yin K, Tang SL Yu XH Tu GH He RF Li JF, et al. (2013). Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin. Acta Pharmacol Sin 34: 837-846.
39. Warrington, KH Jr, and Herzog RW. (2006). Treatment of human disease by adenoassociated viral gene transfer. Hum Genet 119: 571-603.
40. Nakashima M, Toyono T, Akamine, A, and Joyner A. (1999). Expression of growth/.differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev 80: 185-189.
41. Santulli, G, and Totary-Jain H. (2013). Tailoring mTOR-based therapy: molecular evidence, and clinical challenges. Pharmacogenomics 14: 1517-1526.
42. Wu X, Dong X, Wu Z, Cao H, Niu D, Qu J, et al. (2001) A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chinese Sci Bull 46: 485-488.
43. Lu J, Xiang G, Liu M, Mei W, Xiang, L, and Dong J. (2015). Irisin protects against endothelial injury, and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis 243: 438-448.
44. Kobayashi M, Inoue K, Warabi E, Minami, T, and Kodama T. (2005) A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 12: 138-142.
45. Xiang GD, Xu L, Zhao LS, Yue, L, and Hou J. (2006). The relationship between plasma osteoprotegerin, and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 55: 2126-2131.
46. Guangda, X, and Yuhua W. (2003). Apolipoprotein e4 allele, and endotheliumdependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia 46: 514-519.